Analyst Joseph Schwartz from Leerink Partners maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report) and increased the price target to $44.00 from $42.00. Joseph Schwartz’s rating ...
RBC Capital analyst Leonid Timashev assigned a Buy rating to Edgewise Therapeutics (EWTX – Research Report) yesterday and set a price target of $42.00. The company’s shares closed yesterday at $35.43.
Investing.com - Edgewise Therapeutics (NASDAQ: EWTX) reported fourth quarter EPS of $-0.34, in line with the analyst estimate of $-0.34. Revenue for the quarter came ...
After hours: October 25 at 4:02 PM EDT Loading Chart for CMPX ...
After hours: November 12 at 6:17 PM EST Loading Chart for APGE ...
After hours: 18 October at 4:05 pm GMT-4 ...
Dyne Therapeutics Inc. 4.27% $2.94B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback